Collection of Bone Marrow From Donors Treated With or Without Filgrastim

Status Completed

Clinical Trial Summary

This randomized clinical trial is studying the side effects of collection of bone marrow from donors treated with or without filgrastim. Giving colony-stimulating factors, such as filgrastim (G-CSF), to donors helps the stem cells move from the bone marrow to the blood so they can be collected and stored.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate short- and long-term toxicities in bone marrow donors treated with vs without filgrastim before harvest.

II. To compare 10-year mortality and cancer in donors treated with vs without filgrastim.

SECONDARY OBJECTIVES:

I. To correlate the incidence of acute and chronic graft-vs-host disease in the marrow recipients enrolled on COG-ASCT0631 with four parameters assessed in the bone marrow harvests: absolute T-cell numbers, Th1 vs Th2 profile of T-cells, dendritic cell populations, and T-regulatory cell content.

OUTLINE: Donors are randomized to 1 of 2 treatment arms.

ARM I (unstimulated harvest): Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.

ARM II (stimulated harvest): Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.

After completion of study treatment, donors are followed up at 1, 6, and 12 months and then annually for up to 10 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01149096
Study type	Interventional
Source	Children's Oncology Group
Contact
Status	Completed
Phase	Phase 3
Start date	June 14, 2010
Completion date	September 30, 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01230346` - Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer	N/A
Recruiting	`NCT03156309` - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission	Phase 1
Active, not recruiting	`NCT02780401` - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission	Phase 1
Completed	`NCT02099136` - Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers	Phase 2
Completed	`NCT03725449` - Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma	N/A
Completed	`NCT01497431` - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants	Phase 1
Withdrawn	`NCT03120390` - Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors	N/A
Completed	`NCT02090933` - Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers	Phase 2
Terminated	`NCT02735512` - MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
Completed	`NCT02961790` - Oxybutynin Chloride in Managing Hot Flashes	Phase 3
Completed	`NCT02288416` - Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening	N/A
Completed	`NCT01698294` - Biomarkers in Post-Menopausal Women Receiving Flaxseed	N/A
Completed	`NCT00896974` - Study of 9cUAB30 in Healthy Participants	Phase 1
Terminated	`NCT03284346` - Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors	N/A